# EDGAR Filing Document

**Accession Number:** 0001679082
**File Stem:** 0001140361-23-012511
**Filing Date:** 2023-3
**Character Count:** 2861
**Document Hash:** b9307cf041dd932cb5a8a799296fb59e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-012511.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001140361-23-012511

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**EFFECTIVENESS DATE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Myovant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001679082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37929
- **FILM NUMBER:** 23745848

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB
- **BUSINESS PHONE:** 44 207-400-3351

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB

#### <br>

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 15

------

#### CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

#### UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

#### OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

#### OF THE SECURITIES EXCHANGE ACT OF 1934.

#### Commission File Number 001-37929

------

## MYOVANT SCIENCES LTD.

#### (Exact name of registrant as specified in its charter)

------

#### 7th Floor

#### 50 Broadway

#### London

#### SW1H 0DB

#### United Kingdom

#### +44 207 400 3351

#### (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

#### Common Shares, par value $0.000017727 per share

#### (Title of each class of securities covered by this Form)

#### None

#### (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 1

Pursuant to the requirements of the Securities Exchange Act of 1934, Myovant Sciences Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: March 20, 2023 | **MYOVANT SCIENCES LTD.** | **MYOVANT SCIENCES LTD.** |
|  | By: | /s/ Matthew Lang |
|  | Name: | Matthew Lang |
|  | Title: | General Counsel |

---

------

<br>